Previous 10 | Next 10 |
2024-05-16 23:00:27 ET Summary Pfizer's stock has struggled to recover since the pandemic, but its high dividend yield of 5.9% makes it an attractive option for income investors. The company faces risks from upcoming patent expiries and the impact of rising interest rates on its d...
2024-05-16 12:29:52 ET More on GSK, Haleon plc, etc. Haleon: Pressures Are Temporary, But Closer To Fair Value GSK plc (GSK) Q1 2024 Earnings Call Transcript Sales Call GSK expands collaboration with BioVersys on tuberculosis asset alpibectir GSK Non-...
2024-05-16 09:45:00 ET The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You don't have to be rich to invest in the stock market. Whether you're...
2024-05-16 09:00:00 ET Summary The combination of earnings season and a dovish Fed are pushing the markets closer to all-time highs. The Dividend Harvesting Portfolio has reached an all-time high in profitability and account value, with a 13.14% return on invested capital. The...
2024-05-16 06:48:39 ET More on Roche Roche: Value Remains Despite Covid-19 Revenue Growth Loss Roche Holding AG (RHHBY) Q1 2024 Sales/Trading Statement Call Transcript Q1 2024 Sales/ Trading Statement Call J&J, Roche, AstraZeneca poised to have highest or...
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 202...
2024-05-16 05:47:27 ET Pfizer ( NYSE: PFE ) will pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn drug Zantac.... Read the full article on Seeking Alpha For further de...
2024-05-16 00:20:00 ET Summary Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. Our portfolio advanced double digits in Q1, outperforming the Russel...
2024-05-15 11:40:47 ET The temperament on Wall Street is mixed at the moment, split between analysts believing that the next leg up in a bull market is set to take place and others forecasting a bearish move lurking around the corner. For investors looking for more safety, dividend picks ca...
2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...